Can Pediatric Heart Failure Therapy Be Improved? Yes It Can, But …
Paediatr Drugs. 2022 Aug 6. doi: 10.1007/s40272-022-00524-z. Online ahead of print.ABSTRACTGiven the heterogenous etiology of pediatric heart failure (pHF), evidence-based studies improving pHF are unlikely. A paradigm shift towards updated medicine-based evidence is therefore necessary. In view of the life expectancy of children, cardiac regeneration strategies are required. Therefore, age- and disease-related differences in myocardial (receptor) physiology require individualized precision medicine. First-line diuretic therapy, adopted from the treatment of adults with HF with no chance for recovery, should be questioned ...
Source: Paediatric Drugs - August 5, 2022 Category: Pediatrics Authors: Dietmar Schranz Source Type: research
Can Pediatric Heart Failure Therapy Be Improved? Yes It Can, But …
Paediatr Drugs. 2022 Aug 6. doi: 10.1007/s40272-022-00524-z. Online ahead of print.ABSTRACTGiven the heterogenous etiology of pediatric heart failure (pHF), evidence-based studies improving pHF are unlikely. A paradigm shift towards updated medicine-based evidence is therefore necessary. In view of the life expectancy of children, cardiac regeneration strategies are required. Therefore, age- and disease-related differences in myocardial (receptor) physiology require individualized precision medicine. First-line diuretic therapy, adopted from the treatment of adults with HF with no chance for recovery, should be questioned ...
Source: Paediatric Drugs - August 5, 2022 Category: Pediatrics Authors: Dietmar Schranz Source Type: research
Can Pediatric Heart Failure Therapy Be Improved? Yes It Can, But …
Paediatr Drugs. 2022 Aug 6. doi: 10.1007/s40272-022-00524-z. Online ahead of print.ABSTRACTGiven the heterogenous etiology of pediatric heart failure (pHF), evidence-based studies improving pHF are unlikely. A paradigm shift towards updated medicine-based evidence is therefore necessary. In view of the life expectancy of children, cardiac regeneration strategies are required. Therefore, age- and disease-related differences in myocardial (receptor) physiology require individualized precision medicine. First-line diuretic therapy, adopted from the treatment of adults with HF with no chance for recovery, should be questioned ...
Source: Paediatric Drugs - August 5, 2022 Category: Pediatrics Authors: Dietmar Schranz Source Type: research
Case Report: Good cardiac tolerance to Toripalimab in a CVD patient with oral melanoma
Conclusions: This case provided evidence of Toripalimab combined with chemotherapy on melanoma patients with complex cardiovascular diseases. Toripalimab demonstrated a manageable safety profile and durable clinical response. In addition, the standard CHF treatment plays a vital role in the protection of cardiac function. In a cancer patient with complex cardiovascular diseases, standard prophylactic CHF treatment should be applied at an early stage. (Source: Frontiers in Pharmacology)
Source: Frontiers in Pharmacology - August 1, 2022 Category: Drugs & Pharmacology Source Type: research
Co-prescription of metoprolol and CYP2D6-inhibiting antidepressants before and after implementation of an optimized drug interaction database in Norway
ConclusionThe present study suggests that implementation of a drug interaction database providing recommendations on non-interacting drug alternatives contributes to reduced co-prescribing of drug combinations associated with potentially serious adverse effects. (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - July 25, 2022 Category: Drugs & Pharmacology Source Type: research
Hair analysis for beta ‐blockers and calcium‐channel blockers by using liquid chromatography‐tandem mass spectrometry as a tool for monitoring adherence to antihypertensive therapy
The present work aimed at verifying the possibility to use liquid chromatography coupled with mass spectrometry to quantitatively determine antihypertensive drugs in the hair of subjects undergoing chronic treatments. The study includes seven beta-blockers (viz., atenolol, bisoprolol, labetalol, metoprolol, sotalol, nebivolol, and nadolol) and two calcium channel blockers (amlodipine and lercanidipine). The practical applicability of the method was also verified by analyzing 34 authentic hair samples collected from subjects under chronic therapy with those cardiovascular drugs. AbstractAdherence to therapy is the key to a ...
Source: Drug Testing and Analysis - July 21, 2022 Category: Drugs & Pharmacology Authors: Francesco Taus,
Rossella Gottardo,
Marco Ballotari,
Chiara Utzeri,
Franco Tagliaro Tags: SHORT COMMUNICATION Source Type: research
Epinephrine/bisoprolol interaction/sugammadex
(Source: Reactions Weekly)
Source: Reactions Weekly - July 1, 2022 Category: Drugs & Pharmacology Source Type: research
Exploring the kinetic selectivity of drugs targeting the β1‐adrenoceptor
In this study, we report the β1-adrenoceptor binding kinetics of several clinically relevant β1/2-adrenoceptor ( β1/2AR) agonists and antagonists. [3H]-DHA was used to label CHO- β1AR for binding studies. The kinetics of ligand binding was assessed using a competition association binding method. Ligand physicochemical properties, including logD7.4 and the immobilized artificial membrane partition coefficient (KIAM), were assessed using column-based methods. Protein Data Bank (PDB) structures and hydrophobic and electrostatic surface maps were constructed in PyMOL. We demonstrate that the hydrophobic properties of a mol...
Source: Pharmacology Research and Perspectives - June 28, 2022 Category: Drugs & Pharmacology Authors: David A. Sykes,
Mireia Jim énez‐Rosés,
John Reilly,
Robin A. Fairhurst,
Steven J. Charlton,
Dmitry B. Veprintsev Tags: ORIGINAL ARTICLE Source Type: research
Can β-blockers influence regular daily physical activity?
Background:
In hypertension, β-blockers have a high rate of nonadherence to treatment likely because of fatigue.
Methods:
We evaluate daily physical activity and maximal exercise performance in 56 patients with hypertension (grades I–II), with and without β-blockers (bisoprolol 10 mg or atenolol 100 mg) added to standard treatment; 48 patients completed the study. Study tests were performed after 8 weeks of antihypertensive therapy without β blockers and after the following 8 weeks with β-blockers.
Results:
No significant differences between β-blockers were observed. At office measurement, ...
Source: Journal of Hypertension - May 26, 2022 Category: Cardiology Tags: ORIGINAL ARTICLES Source Type: research
Endomyocardial fibrosis in a non ‐tropical patient who presented with chest pain mimicking ACS and left ventricular thrombus, case report
This report aims to increase the attention and awareness of this disease. We present a case of a 53-year-old man referred to the emergency department for sudden chest pain, left-sided and non-radiating lasted for several minutes, awoke him from sleep with no associated symptoms. He is known to have Diabetes type-2 and hypertension on oral therapy. Cardiac markers were within the normal limit. The patient was discharged home with an appointment at the cardiology outpatient clinic. Echocardiography was done and revealed mildly reduced left ventricular (LV) systolic function, Ejection Fraction of 46%, asymmetric LV hypertroph...
Source: Clinical Case Reports - May 23, 2022 Category: General Medicine Authors: Ahmad S. Matarneh,
Yousef M. Ali Hailan,
Sabir Abdul Karim,
Maryam A. Al Kuwari,
Wafer A. Dabdoob Tags: CASE REPORT Source Type: research
Transient but recurrent complete heart block in a patient after COVID-19 vaccination - A case report
CONCLUSION: COVID-19 vaccination may transitorily interfere with cardiac conduction system even in subjects without known underlying heart disease.PMID:35530368 | PMC:PMC9052707 | DOI:10.1016/j.amsu.2022.103694 (Source: Annals of Medicine)
Source: Annals of Medicine - May 9, 2022 Category: Internal Medicine Authors: Hoffer Etienne Pirlet Charles Troisfontaines Pierre Source Type: research
A growing evidence base for the fixed-dose combination of bisoprolol and amlodipine to manage hypertension
CONCLUSIONS: This review adds to growing evidence supporting the efficacy, safety, and tolerability of FDC bisoprolol and amlodipine in managing hypertension.PMID:35510372 | DOI:10.1080/03007995.2022.2072087 (Source: Current Medical Research and Opinion)
Source: Current Medical Research and Opinion - May 5, 2022 Category: Research Authors: Ulrike Hostalek-Gottwald Zbigniew Gaciong Source Type: research
